Sparstolonin B Reduces Estrogen-Dependent Proliferation in Cancer Cells: Possible Role of Ceramide and PI3K/AKT/mTOR Inhibition
2024

Sparstolonin B Reduces Cancer Cell Growth

publication 10 minutes Evidence: high

Author Information

Author(s): Dilber Yağmur, Çeker Hanife Tuğçe, Öztüzün Aleyna, Çırçırlı Bürke, Kırımlıoğlu Esma, Barut Zerrin, Aslan Mutay, Fantacuzzi Marialuigia

Primary Institution: Akdeniz University

Hypothesis

Sparstolonin B could suppress estrogen-dependent cell proliferation in breast and ovarian cancer cells through the inhibition of the PI3K/AKT/mTOR signaling pathway.

Conclusion

Sparstolonin B decreases cancer cell viability and promotes apoptosis by downregulating key signaling proteins.

Supporting Evidence

  • Sparstolonin B significantly decreased cell viability in MCF-7 and OVCAR-3 cells.
  • Cancer cells treated with Sparstolonin B showed a significant drop in the levels of S1P, PI3K, p-AKT, and p-mTOR.
  • Treatment with Sparstolonin B resulted in increased intracellular concentrations of ceramides and apoptosis.

Takeaway

Sparstolonin B is a substance that helps stop cancer cells from growing and makes them die, especially in breast and ovarian cancers.

Methodology

The study evaluated the effects of Sparstolonin B on cancer cell proliferation and apoptosis using various assays including MTT, ELISA, and immunofluorescence.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.3390/ph17121564

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication